Asprihale® is intended for emergency treatment to reduce the risk of vascular mortality in patients with suspected acute myocardial infarction (MI). LOS ANGELES–(BUSINESS WIRE)–Otitopic today announces that it is advancing towards its pivotal PK/PD study following discussions with the FDA. The randomized pivotal study, which is expected to initiate in the […]
Tag: OTITOPIC
OTITOPIC™ New Clinical Trial Results Continue to Demonstrate Inhibition of Platelet Aggregation in Two Minutes With Dry Powder Inhalation of Aspirin Formulation for High Risk Patients to Treat Suspected Acute Myocardial Infarction (MI)
LOS ANGELES–(BUSINESS WIRE)–OTITOPIC – A clinical-stage dry powder inhalation of aspirin pharmaceutical company pioneering the development of antithrombotic treatments for use at the time of suspected acute myocardial infarction (MI), today announced the successful conclusion based on PD results of a clinical trial for its lead drug: Dry Powder Inhalation […]